Prestige Consumer Healthcare (PBH) 10-Q 6 Feb 25 2025 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Dec. 31, 2024	Jan. 31, 2025
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Dec. 31, 2024
Document Transition Report	false
Entity File Number	001-32433
Entity Registrant Name	PRESTIGE CONSUMER HEALTHCARE INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-1297589
Entity Address, Address Line One	660 White Plains Road
Entity Address, City or Town	Tarrytown
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10591
City Area Code	914
Local Phone Number	524-6800
Title of 12(b) Security	Common stock, par value $0.01 per share
Trading Symbol	PBH
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		49,537,839
Entity Central Index Key	0001295947
Current Fiscal Year End Date	--03-31
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Revenues
Total revenues	$ 290,317	$ 282,741	$ 841,244	$ 848,366
Cost of Sales
Cost of sales excluding depreciation	127,360	122,794	370,098	369,772
Cost of sales depreciation	1,908	2,009	6,693	5,963
Cost of sales	129,268	124,803	376,791	375,735
Gross profit	161,049	157,938	464,453	472,631
Operating Expenses
Advertising and marketing	37,945	39,466	118,719	115,799
General and administrative	26,182	26,003	81,159	79,687
Depreciation and amortization	4,960	5,637	16,228	16,869
Total operating expenses	69,087	71,106	216,106	212,355
Operating income	91,962	86,832	248,347	260,276
Other expense
Interest expense, net	11,455	16,575	36,873	51,900
Other expense (income), net	353	682	1,244	(327)
Total other expense, net	11,808	17,257	38,117	51,573
Income before income taxes	80,154	69,575	210,230	208,703
Provision for income taxes	19,122	16,529	45,753	48,822
Net income	$ 61,032	$ 53,046	$ 164,477	$ 159,881
Earnings per share:
Basic (in USD per share)	$ 1.23	$ 1.07	$ 3.31	$ 3.21
Diluted (in USD per share)	$ 1.22	$ 1.06	$ 3.28	$ 3.19
Weighted average shares outstanding:
Basic (in shares)	49,597	49,740	49,711	49,731
Diluted (in shares)	49,993	50,125	50,085	50,134
Comprehensive income, net of tax:
Currency translation adjustments	$ (13,628)	$ 7,465	$ (5,669)	$ 3,035
Total other comprehensive (loss) income	(13,628)	7,465	(5,669)	3,035
Comprehensive income	47,404	60,511	158,808	162,916
Net sales
Revenues
Total revenues	290,002	282,715	840,385	848,321
Other revenues
Revenues
Total revenues	$ 315	$ 26	$ 859	$ 45

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2024	Mar. 31, 2024
Current assets
Cash and cash equivalents	$ 50,874	$ 46,469
Accounts receivable, net of allowance of $16,667 and $16,377, respectively	167,274	176,775
Inventories	151,516	138,717
Prepaid expenses and other current assets	7,500	13,082
Total current assets	377,164	375,043
Property, plant and equipment, net	73,524	76,507
Operating lease right-of-use assets	29,658	11,285
Finance lease right-of-use assets, net	4,943	1,541
Goodwill	527,219	527,733
Intangible assets, net	2,310,650	2,320,583
Other long-term assets	6,339	5,725
Total Assets	3,329,497	3,318,417
Current liabilities
Accounts payable	19,506	38,979
Accrued interest payable	15,206	15,763
Operating lease liabilities, current portion	6,018	4,658
Finance lease liabilities, current portion	900	1,494
Other accrued liabilities	60,915	56,154
Total current liabilities	102,545	117,048
Long-term debt, net	991,969	1,125,804
Deferred income tax liabilities	413,276	403,596
Long-term operating lease liabilities, net of current portion	24,168	7,528
Long-term finance lease liabilities, net of current portion	4,077	172
Other long-term liabilities	5,029	9,185
Total Liabilities	1,541,064	1,663,333
Commitments and Contingencies — Note 14
Stockholders' Equity
Preferred stock	0	0
Common stock	559	555
Additional paid-in capital	588,207	567,448
Treasury stock, at cost - 6,363 shares at December 31, 2024 and 5,680 shares at March 31, 2024	(265,843)	(219,621)
Accumulated other comprehensive loss, net of tax	(40,164)	(34,495)
Retained earnings	1,505,674	1,341,197
Total Stockholders' Equity	1,788,433	1,655,084
Total Liabilities and Stockholders' Equity	$ 3,329,497	$ 3,318,417

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2024	Mar. 31, 2024
Statement of Financial Position [Abstract]
Allowance for doubtful accounts receivable, current	$ 16,667	$ 16,377
Stockholders' Equity:
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	55,939,000	55,501,000
Treasury stock (in shares)	6,363,000	5,680,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Other Comprehensive (Loss) Income	Retained Earnings
Common stock, beginning balance (in shares) at Mar. 31, 2023		54,857,000
Equity, beginning balance at Mar. 31, 2023	$ 1,447,084	$ 548	$ 535,356	$ (189,114)	$ (31,564)	$ 1,131,858
Treasury stock, beginning balance (in shares) at Mar. 31, 2023				5,165,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	$ 10,283		10,283
Exercise of stock options (in shares)	268,900	269,000
Exercise of stock options	$ 10,818	$ 3	10,815
Issuance of shares related to restricted stock (in shares)		203,000
Issuance of shares related to restricted stock	0	$ 2	(2)
Treasury share repurchases (in shares)				515,000
Treasury share repurchases	(30,524)			$ (30,524)
Net income	159,881					159,881
Comprehensive income (loss)	3,035				3,035
Common stock, ending balance (in shares) at Dec. 31, 2023		55,329,000
Equity, ending balance at Dec. 31, 2023	1,600,577	$ 553	556,452	$ (219,638)	(28,529)	1,291,739
Treasury stock, ending balance (in shares) at Dec. 31, 2023				5,680,000
Common stock, beginning balance (in shares) at Sep. 30, 2023		55,291,000
Equity, beginning balance at Sep. 30, 2023	1,535,959	$ 552	552,369	$ (219,661)	(35,994)	1,238,693
Treasury stock, beginning balance (in shares) at Sep. 30, 2023				5,680,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	2,449		2,449
Exercise of stock options (in shares)		38,000
Exercise of stock options	1,635	$ 1	1,634
Treasury share repurchases	23			$ 23
Net income	53,046					53,046
Comprehensive income (loss)	7,465				7,465
Common stock, ending balance (in shares) at Dec. 31, 2023		55,329,000
Equity, ending balance at Dec. 31, 2023	1,600,577	$ 553	556,452	$ (219,638)	(28,529)	1,291,739
Treasury stock, ending balance (in shares) at Dec. 31, 2023				5,680,000
Common stock, beginning balance (in shares) at Mar. 31, 2024		55,501,000
Equity, beginning balance at Mar. 31, 2024	$ 1,655,084	$ 555	567,448	$ (219,621)	(34,495)	1,341,197
Treasury stock, beginning balance (in shares) at Mar. 31, 2024	5,680,000			5,680,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	$ 8,424		8,424
Exercise of stock options (in shares)	243,900	243,000
Exercise of stock options	$ 12,340	$ 3	12,337
Issuance of shares related to restricted stock (in shares)		195,000
Issuance of shares related to restricted stock	(1)	$ 1	(2)
Treasury share repurchases (in shares)				683,000
Treasury share repurchases	(46,222)			$ (46,222)
Net income	164,477					164,477
Comprehensive income (loss)	(5,669)				(5,669)
Common stock, ending balance (in shares) at Dec. 31, 2024		55,939,000
Equity, ending balance at Dec. 31, 2024	$ 1,788,433	$ 559	588,207	$ (265,843)	(40,164)	1,505,674
Treasury stock, ending balance (in shares) at Dec. 31, 2024	6,363,000			6,363,000
Common stock, beginning balance (in shares) at Sep. 30, 2024		55,769,000
Equity, beginning balance at Sep. 30, 2024	$ 1,731,761	$ 557	576,596	$ (263,498)	(26,536)	1,444,642
Treasury stock, beginning balance (in shares) at Sep. 30, 2024				6,329,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	2,865		2,865
Exercise of stock options (in shares)		170,000
Exercise of stock options	8,748	$ 2	8,746
Issuance of shares related to restricted stock (in shares)		0
Issuance of shares related to restricted stock	0	$ 0
Treasury share repurchases (in shares)				34,000
Treasury share repurchases	(2,345)			$ (2,345)
Net income	61,032					61,032
Comprehensive income (loss)	(13,628)				(13,628)
Common stock, ending balance (in shares) at Dec. 31, 2024		55,939,000
Equity, ending balance at Dec. 31, 2024	$ 1,788,433	$ 559	$ 588,207	$ (265,843)	$ (40,164)	$ 1,505,674
Treasury stock, ending balance (in shares) at Dec. 31, 2024	6,363,000			6,363,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Operating Activities
Net income	$ 164,477	$ 159,881
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	22,921	22,832
Loss on disposal of property and equipment	83	231
Deferred and other income taxes	7,278	14,892
Amortization of debt origination costs	1,316	3,726
Stock-based compensation costs	8,424	10,283
Non-cash operating lease cost	5,322	4,494
Changes in operating assets and liabilities:
Accounts receivable	8,874	(7,017)
Inventories	(13,385)	13,790
Prepaid expenses and other current assets	5,558	(2,605)
Accounts payable	(18,851)	(23,964)
Accrued liabilities	4,359	(7,732)
Operating lease liabilities	(5,721)	(5,259)
Other	(988)	(1,533)
Net cash provided by operating activities	189,667	182,019
Investing Activities
Purchases of property, plant and equipment	(4,745)	(6,407)
Acquisition and other	(9,228)	1,300
Net cash used in investing activities	(13,973)	(5,107)
Financing Activities
Term loan repayments	(135,000)	(150,000)
Payments of debt costs	0	(769)
Payments of finance leases	(1,899)	(2,112)
Proceeds from exercise of stock options	12,340	10,818
Fair value of shares surrendered as payment of tax withholding	(5,832)	(5,508)
Repurchase of common stock	(40,196)	(25,000)
Net cash used in financing activities	(170,587)	(172,571)
Effects of exchange rate changes on cash and cash equivalents	(702)	785
Increase in cash and cash equivalents	4,405	5,126
Cash and cash equivalents - beginning of period	46,469	58,489
Cash and cash equivalents - end of period	50,874	63,615
Interest paid	37,427	49,666
Income taxes paid	$ 33,512	$ 38,606

Business and Basis of Presentat

Business and Basis of Presentation	9 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business and Basis of Presentation	Business and Basis of Presentation Nature of Business Prestige Consumer Healthcare Inc. (referred to herein as the “Company” or “we,” which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Consumer Healthcare Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (“OTC”) healthcare products to mass merchandisers, drug, food, dollar, convenience and club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Prestige Consumer Healthcare Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 7 to these Condensed Consolidated Financial Statements. Economic Environment There has been economic uncertainty in the United States and globally due to several factors, including global supply chain constraints, changes in interest rates, a high inflationary environment, geopolitical events and evolving U.S. and international tariffs. We expect economic conditions will continue to be highly volatile and uncertain, put pressure on prices and supply, and could affect demand for our products. We have continued to see changes in the purchasing patterns of our end customers, including a shift in many markets to purchasing our products online. The volatile environment has impacted the supply of labor and raw materials and exacerbated rising input costs. We have and may continue to experience shortages, delays and backorders for certain ingredients and products, difficulty scheduling shipping for our products, as well as price increases from many of our suppliers for both shipping and product costs. Certain of our third-party manufacturers are currently having, and have had in the past, difficulty meeting demand, which is and has caused shortages of our products, particularly eye care products. These shortages negatively impacted our results of operations, and we expect further shortages may have a negative impact on our sales. If conditions cause further disruption in the global supply chain, the availability of labor and materials or otherwise further increase costs, it may materially affect our operations and those of third parties on which we rely, including causing material disruptions in the supply and distribution of our products. The extent to which these conditions impact our results and liquidity will depend on future developments, which are highly uncertain and cannot be predicted, including global supply chain constraints, inflation, global conflicts and trade actions/disputes, and the potential for further outbreaks of severe illnesses. These effects could have a material adverse impact on our business, liquidity, capital resources, and results of operations and those of the third parties on which we rely. Basis of Presentation The unaudited Condensed Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, these Condensed Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31st of each year. References in these Condensed Consolidated Financial Statements or related notes to a year (e.g., 2025) mean our fiscal year ending or ended on March 31st of that year. Operating results for the nine months ended December 31, 2024 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2025. These unaudited Condensed Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2024. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. Our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and accounting for income taxes and related uncertain tax positions. Recently Issued Accounting Pronouncements In November 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses . This ASU requires entities to disclose, in the notes to financial statements, specified information about certain costs and expenses at each interim and annual reporting period. Required disclosures include, among other things, the amount of purchases of inventory, employee compensation, depreciation, and intangible asset amortization. In addition, entities will be required to disclose the total amount of selling expenses and, in annual reporting periods, their definition of selling expenses. This ASU is effective for entities for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. We are currently evaluating the impact that this ASU may have on our Consolidated Financial Statement disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures . The amendments in this update require that entities disclose, on an annual basis, specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. The amendments in this update also require disclosure, on an annual basis, of income taxes paid, disaggregated by federal, state and foreign taxes and disaggregated by individual jurisdictions in which income taxes paid are equal to or greater than five percent of total income taxes paid. In addition, the amendments in this update also require that income (or loss) before income taxes be disaggregated between domestic and foreign and income tax expense (or benefit) be disaggregated by federal, state and foreign. This ASU is effective for annual periods beginning after December 15, 2024. We are currently evaluating the impact that this ASU may have on our Consolidated Financial Statement disclosures. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures . The amendments in this update intend to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. This ASU requires disclosure of significant segment expenses that are regularly provided to the chief operating decision maker, the addition of a category for other segment items by reportable segment, that all annual segment disclosures be disclosed in interim periods, and other related segment disclosures. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. We are currently evaluating the impact that this ASU may have on our Consolidated Financial Statement disclosures.

Inventories

Inventories	9 Months Ended
	Dec. 31, 2024
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consist of the following: (In thousands) December 31, 2024 March 31, 2024 Components of Inventories Packaging and raw materials $ 19,437 $ 19,210 Work in process 3,042 636 Finished goods 129,037 118,871 Inventories $ 151,516 $ 138,717

Goodwill

Goodwill	9 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill A reconciliation of the activity affecting goodwill by operating segment is as follows: (In thousands) North American OTC International OTC Consolidated Balance - March 31, 2024 Goodwill $ 711,452 $ 30,384 $ 741,836 Accumulated impairment loss (212,516) (1,587) (214,103) Balance - March 31, 2024 498,936 28,797 527,733 Adjustment related to acquisition — 309 309 Effects of foreign currency exchange rates — (823) (823) Balance - December 31, 2024 Goodwill 711,452 29,870 741,322 Accumulated impairment loss (212,516) (1,587) (214,103) Balance - December 31, 2024 $ 498,936 $ 28,283 $ 527,219 At February 29, 2024, the date of our annual impairment review, the estimated fair value exceeded the carrying value for all reporting units and, accordingly, no impairment charge was taken. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties related to future sales, gross margins, and advertising and marketing expenses, which can be impacted by increases in competition, changing consumer preferences, technical advances, supply chain constraints, labor shortages, and inflation. The discount rate assumption may be influenced by such factors as changes in interest rates and rates of inflation, which can have an impact on the determination of fair value. If these assumptions are adversely affected, we may be required to record impairment charges in the future. As of December 31, 2024, we determined no events have occurred that would indicate potential impairment of goodwill.

Intangible Assets, net

Intangible Assets, net	9 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, net	Intangible Assets, net A reconciliation of the activity affecting intangible assets, net is as follows: (In thousands) Indefinite- Finite-Lived Totals Gross Carrying Amounts Balance — March 31, 2024 $ 2,167,162 $ 411,258 $ 2,578,420 Additions (a) 6,850 1,400 8,250 Effects of foreign currency exchange rates (3,511) (911) (4,422) Balance — December 31, 2024 $ 2,170,501 $ 411,747 $ 2,582,248 Accumulated Amortization Balance — March 31, 2024 $ — $ 257,837 $ 257,837 Additions — 13,975 13,975 Effects of foreign currency exchange rates — (214) (214) Balance — December 31, 2024 $ — $ 271,598 $ 271,598 Intangible assets, net - December 31, 2024 $ 2,170,501 $ 140,149 $ 2,310,650 (a) Amounts relate to our acquisition of Hydralyte intellectual property on October 1, 2024, giving us rights to the Hydralyte intellectual property in all remaining jurisdictions with the exception of the United States. Amortization expense was $4.2 million and $14.0 million for the three and nine months ended December 31, 2024, respectively, and $4.9 million and $14.8 million for the three and nine months ended December 31, 2023, respectively. Finite-lived intangible assets are expected to be amortized over their estimated useful life, which ranges from a period of 10 to 24 years, and the estimated amortization expense for each of the five succeeding years and the periods thereafter is as follows (in thousands): (In thousands) Year Ending March 31, Amount 2025 (remaining three months ended March 31, 2025) $ 4,201 2026 16,213 2027 14,621 2028 12,286 2029 12,286 Thereafter 80,542 $ 140,149 At February 29, 2024, the date of our annual impairment review, the estimated fair value exceeded the carrying value for all intangible assets and, accordingly, no impairment charge was taken. The assumptions subject to significant uncertainties in the impairment analysis include the discount rate utilized in the analysis, as well as future sales, gross margins, and advertising and marketing expenses. The discount rate assumption may be influenced by such factors as changes in interest rates and rates of inflation, which can have an impact on the determination of fair value. Additionally, should the related fair values of intangible assets be adversely affected as a result of declining sales or margins caused by competition, changing consumer needs or preferences, technological advances, changes in advertising and marketing expenses, or supply chain constraints, labor shortages, or inflation, we may be required to record impairment charges in the future. As of December 31, 2024, no events have occurred that would indicate potential impairment of intangible assets.

Leases

Leases	9 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Leases	Leases We lease real estate and equipment for use in our operations. The components of lease expense for the three and nine months ended December 31, 2024 and 2023 were as follows: Three Months Ended December 31, Nine Months Ended December 31, (In thousands) 2024 2023 2024 2023 Finance lease cost: Amortization of right-of-use assets $ 240 $ 665 $ 1,569 $ 1,994 Interest on lease liabilities 82 20 94 74 Operating lease cost 1,986 1,624 5,395 4,872 Short term lease cost 38 34 101 101 Variable lease cost 15,120 14,488 47,668 47,885 Total net lease cost $ 17,466 $ 16,831 $ 54,827 $ 54,926 As of December 31, 2024, the maturities of lease liabilities were as follows: (In thousands) Year Ending March 31, Operating Leases Finance Total 2025 (remaining three months ending March 31, 2025) $ 1,909 $ 303 $ 2,212 2026 7,592 1,211 8,803 2027 7,237 1,211 8,448 2028 6,835 1,211 8,046 2029 5,554 1,205 6,759 Thereafter 6,300 701 7,001 Total undiscounted lease payments 35,427 5,842 41,269 Less amount of lease payments representing interest (5,241) (865) (6,106) Total present value of lease payments $ 30,186 $ 4,977 $ 35,163 The weighted average remaining lease term and weighted average discount rate were as follows: December 31, 2024 Weighted average remaining lease term (years) Operating leases 4.97 Finance leases 4.88 Weighted average discount rate Operating leases 6.53 % Finance leases 6.93 %
Leases	Leases We lease real estate and equipment for use in our operations. The components of lease expense for the three and nine months ended December 31, 2024 and 2023 were as follows: Three Months Ended December 31, Nine Months Ended December 31, (In thousands) 2024 2023 2024 2023 Finance lease cost: Amortization of right-of-use assets $ 240 $ 665 $ 1,569 $ 1,994 Interest on lease liabilities 82 20 94 74 Operating lease cost 1,986 1,624 5,395 4,872 Short term lease cost 38 34 101 101 Variable lease cost 15,120 14,488 47,668 47,885 Total net lease cost $ 17,466 $ 16,831 $ 54,827 $ 54,926 As of December 31, 2024, the maturities of lease liabilities were as follows: (In thousands) Year Ending March 31, Operating Leases Finance Total 2025 (remaining three months ending March 31, 2025) $ 1,909 $ 303 $ 2,212 2026 7,592 1,211 8,803 2027 7,237 1,211 8,448 2028 6,835 1,211 8,046 2029 5,554 1,205 6,759 Thereafter 6,300 701 7,001 Total undiscounted lease payments 35,427 5,842 41,269 Less amount of lease payments representing interest (5,241) (865) (6,106) Total present value of lease payments $ 30,186 $ 4,977 $ 35,163 The weighted average remaining lease term and weighted average discount rate were as follows: December 31, 2024 Weighted average remaining lease term (years) Operating leases 4.97 Finance leases 4.88 Weighted average discount rate Operating leases 6.53 % Finance leases 6.93 %

Other Accrued Liabilities

Other Accrued Liabilities	9 Months Ended
	Dec. 31, 2024
Payables and Accruals [Abstract]
Other Accrued Liabilities	Other Accrued Liabilities Other accrued liabilities consist of the following: (In thousands) December 31, 2024 March 31, 2024 Accrued marketing costs $ 26,364 $ 24,053 Accrued compensation costs 11,300 12,221 Accrued broker commissions 1,881 1,309 Income taxes payable 436 2,569 Accrued professional fees 8,041 5,046 Accrued production costs 6,707 4,166 Other accrued liabilities 6,186 6,790 $ 60,915 $ 56,154

Long-Term Debt

Long-Term Debt	9 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt Long-term debt consists of the following, as of the dates indicated: (In thousands, except percentages) December 31, 2024 March 31, 2024 2021 Senior Notes bearing interest at 3.750%, with interest payable on April 1 and October 1 of each year. The 2021 Senior Notes mature on April 1, 2031. $ 600,000 $ 600,000 2019 Senior Notes bearing interest at 5.125%, with interest payable on January 15 and July 15 of each year. The 2019 Senior Notes mature on January 15, 2028. 400,000 400,000 2012 Term B-5 Loans bearing interest at the Borrower's option at SOFR plus a margin of 2.00% plus a credit spread adjustment, due on July 1, 2028. — 135,000 Long-term debt 1,000,000 1,135,000 Less: unamortized debt costs (8,031) (9,196) Long-term debt, net $ 991,969 $ 1,125,804 At December 31, 2024, we had no balance outstanding on the asset-based revolving credit facility originally entered into on January 31, 2012 (the "2012 ABL Revolver") and a borrowing capacity of $163.8 million. During the three months ended December 31, 2024, we repaid the balance of our 2012 Term B-5 Loans under the term loan due 2028 originally entered into on January 31, 2012 (the "2012 B-5 Term Loan"). As of December 31, 2024, aggregate future principal payments required in accordance with the terms of the indentures governing the senior unsecured notes due 2031 (the "2021 Senior Notes") and the senior unsecured notes due 2028 (the "2019 Senior Notes") are as follows: (In thousands) Year Ending March 31, Amount 2025 (remaining three months ending March 31, 2025) $ — 2026 — 2027 — 2028 400,000 2029 — Thereafter 600,000 $ 1,000,000

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts. FASB Accounting Standards Codification ("ASC") 820, Fair Value Measurements , requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. ASC 820 established market (observable inputs) as the preferred source of fair value, to be followed by our assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created: Level 1 - Quoted market prices for identical instruments in active markets; Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and Level 3 - Unobservable inputs developed by us using estimates and assumptions reflective of those that would be utilized by a market participant. The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the 2021 Senior Notes, the 2019 Senior Notes, and the 2012 Term B-5 Loans are measured in Level 2 of the above hierarchy. The summary below details the carrying amounts and estimated fair values of these instruments at December 31, 2024 and March 31, 2024. December 31, 2024 March 31, 2024 (In thousands) Carrying Value Fair Value Carrying Value Fair Value 2019 Senior Notes 400,000 389,500 400,000 389,000 2021 Senior Notes 600,000 526,500 600,000 522,750 2012 Term B-5 Loans — — 135,000 135,506

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Dec. 31, 2024
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders' Equity We are authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share. The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof. Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of outstanding stock having priority rights as to dividends. No dividends have been declared or paid on our common stock through December 31, 2024. On May 6, 2024, the Company's Board of Directors authorized the repurchase of up to $300.0 million of the Company's issued and outstanding common stock. Under the authorization, the Company may purchase common stock utilizing open market transactions, transactions structured through investment banking institutions, in privately-negotiated transactions, by direct purchases of common stock or a combination of the foregoing in compliance with the applicable rules and regulations of the U.S. Securities and Exchange Commission. During the three and nine months ended December 31, 2024 and 2023, we repurchased shares of our common stock and recorded them as treasury stock. Our share repurchases consisted of the following: Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Shares repurchased pursuant to the provisions of the various employee restricted stock awards: Number of shares — — 83,124 88,953 Average price per share — $ — $70.16 $61.92 Total amount repurchased — $ — $5.8 million $5.5 million Shares repurchased in conjunction with our share repurchase program: Number of shares 34,104 — 599,948 426,479 Average price per share $70.43 $ — $67.00 $58.62 Total amount repurchased $2.4 million $ — $40.2 million $25.0 million

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	9 Months Ended
	Dec. 31, 2024
Stockholders' Equity Note [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss Accumulated other comprehensive loss consisted of the following at December 31, 2024 and March 31, 2024: (In thousands) December 31, 2024 March 31, 2024 Components of Accumulated Other Comprehensive Loss Cumulative translation adjustment $ (40,889) $ (35,220) Unrecognized net gain on pension plans, net of tax of $(217) and $(217), respectively 725 725 Accumulated other comprehensive loss, net of tax $ (40,164) $ (34,495)

Earnings Per Share

Earnings Per Share	9 Months Ended
	Dec. 31, 2024
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share The following table sets forth the computation of basic and diluted earnings per share: Three Months Ended December 31, Nine Months Ended December 31, (In thousands, except per share data) 2024 2023 2024 2023 Numerator Net income $ 61,032 $ 53,046 $ 164,477 $ 159,881 Denominator Denominator for basic earnings per share — weighted average shares outstanding 49,597 49,740 49,711 49,731 Dilutive effect of unvested restricted stock units and options issued to employees and directors 396 385 374 403 Denominator for diluted earnings per share 49,993 50,125 50,085 50,134 Earnings per Common Share: Basic earnings per share $ 1.23 $ 1.07 $ 3.31 $ 3.21 Diluted earnings per share $ 1.22 $ 1.06 $ 3.28 $ 3.19

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “2005 Plan”), which provided for grants of up to a maximum of 5.0 million shares of restricted stock, stock options, restricted stock units ("RSUs") and other equity-based awards. In June 2014, the Board of Directors approved, and in July 2014, our stockholders ratified, an increase of an additional 1.8 million shares of our common stock for issuance under the 2005 Plan, among other changes. On June 23, 2020, the Board of Directors adopted the Prestige Consumer Healthcare Inc. 2020 Long-Term Incentive Plan (the “2020 Plan”). The 2020 Plan became effective on August 4, 2020, upon the approval of the 2020 Plan by our stockholders. On June 23, 2020, a total of 2,827,210 shares were available for issuance under the 2020 Plan (comprised of 2,000,000 new shares plus 827,210 shares that were unissued under the 2005 Plan). Since the 2020 Plan became effective, all equity awards have been made from the 2020 Plan, and the Company will not grant any additional awards under the 2005 Plan. On January 6, 2025, we announced that Christine Sacco, our Chief Financial Officer, has also been appointed Chief Operating Officer, effective that same day. In connection with Ms. Sacco's appointment as Chief Operating Officer, the Company granted Ms. Sacco 21,136 RSUs, which vest in their entirety on the four-year anniversary of the date of grant, subject to Ms. Sacco's continued employment. Upon vesting, the units will be settled in shares of our common stock. At December 31, 2024, there were 1.6 million shares available for issuance under the 2020 Plan. The following table provides information regarding our stock-based compensation: Three Months Ended December 31, Nine Months Ended December 31, (In thousands) 2024 2023 2024 2023 Pre-tax stock-based compensation costs charged against income $ 2,865 $ 2,449 $ 8,424 $ 10,283 Income tax benefit recognized on compensation costs $ 356 $ 241 $ 1,085 $ 910 Total fair value of options and RSUs vested during the period $ — $ — $ 12,185 $ 12,213 Cash received from the exercise of stock options $ 8,748 $ 1,635 $ 12,340 $ 10,818 Tax benefits realized from tax deductions resulting from RSU issuances and stock option exercises $ 319 $ 351 $ 1,361 $ 1,490 At December 31, 2024, there were $3.2 million of unrecognized compensation costs related to unvested stock options under the 2005 Plan and the 2020 Plan, excluding an estimate for forfeitures which may occur. We expect to recognize such costs over a weighted average period of 1.9 years. At December 31, 2024, there were $12.2 million of unrecognized compensation costs related to unvested RSUs and performance stock units ("PSUs") under the 2005 Plan and the 2020 Plan, excluding an estimate for forfeitures which may occur. We expect to recognize such costs over a weighted average period of 1.9 years. Restricted Stock Units The fair value of the RSUs is determined using the closing price of our common stock on the date of the grant. A summary of the RSUs granted under the 2005 Plan and the 2020 Plan is presented below: RSUs Shares (in thousands) Weighted Nine Months Ended December 31, 2023 Unvested at March 31, 2023 409.0 $ 47.17 Granted 157.1 62.06 Incremental performance shares 41.4 — Vested (205.0) 43.17 Forfeited (10.6) 52.68 Unvested at December 31, 2023 391.9 54.43 Vested at December 31, 2023 110.2 38.77 Nine Months Ended December 31, 2024 Unvested at March 31, 2024 391.9 $ 54.43 Granted 145.7 69.70 Incremental performance shares 41.1 — Vested (192.7) 47.60 Forfeited (4.9) 59.31 Unvested at December 31, 2024 381.1 62.57 Vested at December 31, 2024 108.5 40.87 Options The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions presented below: Nine Months Ended December 31, 2024 2023 Expected volatility 30.4% - 30.8% 30.2% - 31.6% Expected dividends $ — $ — Expected term in years 6.0 to 7.0 6.0 to 7.0 Risk-free rate 4.5% 3.6% to 4.1% Weighted average grant date fair value of options granted $ 27.97 $ 23.79 A summary of option activity under the 2005 Plan and the 2020 Plan is as follows: Options Shares (in thousands) Weighted Weighted Aggregate Nine Months Ended December 31, 2023 Outstanding at March 31, 2023 1,081.0 $ 43.96 Granted 131.1 61.81 Exercised (268.9) 40.23 Forfeited (41.0) 54.15 Expired (2.8) 54.47 Outstanding at December 31, 2023 899.4 47.18 6.2 $ 12,703 Vested at December 31, 2023 606.2 43.23 5.0 $ 10,903 Nine Months Ended December 31, 2024 Outstanding at March 31, 2024 728.0 $ 48.30 Granted 109.7 69.94 Exercised (243.9) 50.59 Forfeited (15.6) 60.87 Outstanding at December 31, 2024 578.2 51.10 6.8 $ 15,608 Vested at December 31, 2024 349.9 42.65 5.7 $ 12,399 The aggregate intrinsic value of options exercised during the nine months ended December 31, 2024 was $6.6 million.

Income Taxes

Income Taxes	9 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Numerous countries have agreed to a statement in support of the Organization for Economic Cooperation and Development ("OECD") model rules that propose a global minimum tax rate of 15%. Certain countries have enacted legislation incorporating the agreed upon global minimum tax effective in 2024. This legislation has not and is not expected to have a material impact on our Consolidated Financial Statements. Income taxes are recorded in our quarterly financial statements based on our estimated annual effective income tax rate, subject to adjustments for discrete events, should they occur. The effective tax rates used in the calculation of income taxes were 23.9% and 23.8% for the three months ended December 31, 2024 and 2023, respectively. The effective tax rates used in the calculation of income taxes were 21.8% and 23.4% for the nine months ended December 31, 2024 and 2023, respectively. The decrease in the effective tax rate for the nine months ended December 31, 2024 compared to the nine months ended December 31, 2023 was due to discrete items primarily pertaining to the release of a reserve for uncertain tax positions due to the statute of limitations expiring.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies We are involved from time to time in legal matters and other claims incidental to our business. We review outstanding claims and proceedings internally and with external counsel as necessary to assess the probability and amount of a potential loss. These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a contingency accrual should be established or if any existing contingency accrual should be adjusted. The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded contingency accrual. In addition, because it is not permissible under GAAP to establish a litigation contingency accrual until the loss is both probable and estimable, in some cases there may be insufficient time to establish a contingency accrual prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement). We believe the reasonably possible losses from resolution of routine legal matters and other claims incidental to our business will not have a material effect on our financial statements.

Concentrations of Risk

Concentrations of Risk	9 Months Ended
	Dec. 31, 2024
Risks and Uncertainties [Abstract]
Concentrations of Risk	Concentrations of Risk Our revenues are concentrated in the area of OTC Healthcare. We sell our products to mass merchandisers, drug, food, dollar, convenience and club stores and e-commerce channels. During the three and nine months ended December 31, 2024, approximately 38% and 37%, respectively, of our gross revenues were derived from our five top selling brands. During the three and nine months ended December 31, 2023, approximately 37% and 38%, respectively, of our gross revenues were derived from our five top selling brands. Walmart accounted for approximately 20% of our gross revenues for the three and nine months ended December 31, 2024. Walmart accounted for approximately 19% and 20%, respectively, of our gross revenues for the three and nine months ended December 31, 2023. Amazon accounted for approximately 12% of gross revenues for the three and nine months ended December 31, 2024. Amazon accounted for approximately 11% and 10%, respectively, of gross revenues for the three and nine months ended December 31, 2023. Our product distribution in the United States is managed by a third-party through one primary distribution center in Clayton, Indiana. We also operate a manufacturing facility in Lynchburg, Virginia, which manufactures certain of our Fleet , Monistat, Summer's Eve and Debrox products, and a manufacturing facility in Victoria, Australia, which manufactures some of our Hydralyte and Fess products. A natural disaster, such as tornado, earthquake, flood, or fire, at our distribution center or our own or a third-party manufacturing facility could damage our inventory and/or materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost. In addition, a serious disruption caused by performance or contractual issues with our third-party distribution manager, or labor shortages or contagious disease outbreaks or other public health emergencies at our distribution center or manufacturing facilities could also materially impact our product distribution. Any disruption could result in increased costs, expense and/or shipping times, and could harm our reputation and cause us to incur customer fees and penalties. We could also incur significantly higher costs and experience longer lead times should we be required to replace our distribution center, the third-party distribution manager or the manufacturing facilities. As a result, any serious disruption could have a material adverse effect on our business, financial condition and results of operations. At December 31, 2024, we had relationships with 102 third-party manufacturers. Of those, we had long-term contracts with 27 manufacturers that produced items that accounted for approximately 73% of gross sales for the nine months ended December 31, 2024. At December 31, 2023, we had relationships with 129 third-party manufacturers. Of those, we had long-term contracts with 27 manufacturers that produced items that accounted for approximately 72% of gross sales for the nine months ended December 31, 2023. One of our suppliers, a privately owned pharmaceutical manufacturer with whom we have a long-term supply agreement, produced products that accounted for more than 10% of our gross revenues for the nine months ended December 31, 2024 and 2023. This manufacturer accounted for approximately 21% of our gross revenues for the nine months ended December 31, 2024, and approximately 20% of our gross revenues for the nine months ended December 31, 2023, while we accounted for a significant portion of their gross revenues over both time periods. No other single third-party supplier produces products that account for 10% or more of our gross revenues. The fact that we do not have long-term contracts with certain manufacturers means that they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business and results of operations. Although we are continually in the process of negotiating long-term contracts with certain key manufacturers, we may not be able to reach a timely agreement, which could have a material adverse effect on our business and results of operations.

Business Segments

Business Segments	9 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Business Segments	Business Segments Our current reportable segments consist of (i) North American OTC Healthcare and (ii) International OTC Healthcare. We evaluate the performance of our operating segments and allocate resources to these segments based primarily on contribution margin, which we define as gross profit less advertising and marketing expenses. The tables below summarize information about our reportable segments. Three Months Ended December 31, 2024 (In thousands) North American OTC International OTC Consolidated Total segment revenues* $ 238,934 $ 51,383 $ 290,317 Cost of sales 108,067 21,201 129,268 Gross profit 130,867 30,182 161,049 Advertising and marketing 30,995 6,950 37,945 Contribution margin $ 99,872 $ 23,232 $ 123,104 Other operating expenses 31,142 Operating income $ 91,962 * Intersegment revenues of $0.9 million were eliminated from the North American OTC Healthcare segment. Nine Months Ended December 31, 2024 (In thousands) North American OTC International OTC Consolidated Total segment revenues* 711,061 $ 130,183 $ 841,244 Cost of sales 321,408 55,383 376,791 Gross profit 389,653 74,800 464,453 Advertising and marketing 99,637 19,082 118,719 Contribution margin $ 290,016 $ 55,718 $ 345,734 Other operating expenses 97,387 Operating income $ 248,347 * Intersegment revenues of $2.5 million were eliminated from the North American OTC Healthcare segment. Three Months Ended December 31, 2023 (In thousands) North American OTC International OTC Consolidated Total segment revenues* $ 236,565 $ 46,176 $ 282,741 Cost of sales 106,090 18,713 124,803 Gross profit 130,475 27,463 157,938 Advertising and marketing 33,917 5,549 39,466 Contribution margin $ 96,558 $ 21,914 $ 118,472 Other operating expenses 31,640 Operating income $ 86,832 * Intersegment revenues of $0.5 million were eliminated from the North American OTC Healthcare segment. Nine Months Ended December 31, 2023 (In thousands) North American OTC International OTC Consolidated Total segment revenues* $ 727,131 $ 121,235 $ 848,366 Cost of sales 323,632 52,103 375,735 Gross profit 403,499 69,132 472,631 Advertising and marketing 100,707 15,092 115,799 Contribution margin $ 302,792 $ 54,040 $ 356,832 Other operating expenses 96,556 Operating income $ 260,276 * Intersegment revenues of $2.5 million were eliminated from the North American OTC Healthcare segment. The tables below summarize information about our segment revenues from similar product groups. Three Months Ended December 31, 2024 (In thousands) North American OTC International OTC Consolidated Analgesics $ 29,314 $ 1,668 $ 30,982 Cough & Cold 22,984 6,347 29,331 Women's Health 53,686 4,439 58,125 Gastrointestinal 42,521 26,469 68,990 Eye & Ear Care 38,895 6,783 45,678 Dermatologicals 28,546 2,109 30,655 Oral Care 19,869 3,211 23,080 Other OTC 3,119 357 3,476 Total segment revenues $ 238,934 $ 51,383 $ 290,317 Nine Months Ended December 31, 2024 (In thousands) North American OTC International OTC Consolidated Analgesics $ 83,472 $ 4,025 $ 87,497 Cough & Cold 60,999 18,304 79,303 Women's Health 158,490 14,560 173,050 Gastrointestinal 128,719 58,347 187,066 Eye & Ear Care 118,354 18,240 136,594 Dermatologicals 93,789 6,076 99,865 Oral Care 58,241 9,696 67,937 Other OTC 8,997 935 9,932 Total segment revenues $ 711,061 $ 130,183 $ 841,244 Three Months Ended December 31, 2023 (In thousands) North American OTC International OTC Consolidated Analgesics $ 28,680 $ 1,586 $ 30,266 Cough & Cold 27,359 5,814 33,173 Women's Health 53,076 5,190 58,266 Gastrointestinal 38,919 22,707 61,626 Eye & Ear Care 38,503 6,569 45,072 Dermatologicals 26,603 1,165 27,768 Oral Care 20,362 3,100 23,462 Other OTC 3,063 45 3,108 Total segment revenues $ 236,565 $ 46,176 $ 282,741 Nine Months Ended December 31, 2023 (In thousands) North American OTC International OTC Consolidated Analgesics $ 85,838 $ 3,814 $ 89,652 Cough & Cold 73,703 19,129 92,832 Women's Health 163,031 17,218 180,249 Gastrointestinal 122,303 49,678 171,981 Eye & Ear Care 117,719 17,715 135,434 Dermatologicals 94,299 3,972 98,271 Oral Care 61,400 9,591 70,991 Other OTC 8,838 118 8,956 Total segment revenues $ 727,131 $ 121,235 $ 848,366

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Pay vs Performance Disclosure
Net income	$ 61,032	$ 53,046	$ 164,477	$ 159,881

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	9 Months Ended
	Dec. 31, 2024 shares	Dec. 31, 2024 shares
Trading Arrangements, by Individual
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Mary Beth Fritz [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		The following is a summary of the material terms of the contracts, instructions or written plans for the purchase or sale of the Company's securities adopted or terminated by our officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) or directors during the three months ended December 31, 2024: Name and Position Date Action Satisfies Affirmative Defense under Rule 10b5-(c) Expiration Date Total Ordinary Shares to be Sold Mary Beth Fritz December 2, 2024 Adoption X June 30, 2025 10,713 Senior Vice President Quality & Regulatory Affairs
Name	Mary Beth Fritz
Title	Senior Vice PresidentQuality & Regulatory Affairs
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	December 2, 2024
Expiration Date	June 30, 2025
Arrangement Duration	210 days
Aggregate Available	10,713	10,713

Business and Basis of Present_2

Business and Basis of Presentation (Policies)	9 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The unaudited Condensed Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, these Condensed Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31st of each year. References in these Condensed Consolidated Financial Statements or related notes to a year (e.g., 2025) mean our fiscal year ending or ended on March 31st of that year. Operating results for the nine months ended December 31, 2024 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2025. These unaudited Condensed Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2024.
Use of Estimates	Use of Estimates
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In November 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses . This ASU requires entities to disclose, in the notes to financial statements, specified information about certain costs and expenses at each interim and annual reporting period. Required disclosures include, among other things, the amount of purchases of inventory, employee compensation, depreciation, and intangible asset amortization. In addition, entities will be required to disclose the total amount of selling expenses and, in annual reporting periods, their definition of selling expenses. This ASU is effective for entities for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. We are currently evaluating the impact that this ASU may have on our Consolidated Financial Statement disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures . The amendments in this update require that entities disclose, on an annual basis, specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. The amendments in this update also require disclosure, on an annual basis, of income taxes paid, disaggregated by federal, state and foreign taxes and disaggregated by individual jurisdictions in which income taxes paid are equal to or greater than five percent of total income taxes paid. In addition, the amendments in this update also require that income (or loss) before income taxes be disaggregated between domestic and foreign and income tax expense (or benefit) be disaggregated by federal, state and foreign. This ASU is effective for annual periods beginning after December 15, 2024. We are currently evaluating the impact that this ASU may have on our Consolidated Financial Statement disclosures. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures . The amendments in this update intend to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. This ASU requires disclosure of significant segment expenses that are regularly provided to the chief operating decision maker, the addition of a category for other segment items by reportable segment, that all annual segment disclosures be disclosed in interim periods, and other related segment disclosures. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. We are currently evaluating the impact that this ASU may have on our Consolidated Financial Statement disclosures.

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Dec. 31, 2024
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consist of the following: (In thousands) December 31, 2024 March 31, 2024 Components of Inventories Packaging and raw materials $ 19,437 $ 19,210 Work in process 3,042 636 Finished goods 129,037 118,871 Inventories $ 151,516 $ 138,717

Goodwill (Tables)

Goodwill (Tables)	9 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Reconciliation of the Activity Affecting Goodwill	A reconciliation of the activity affecting goodwill by operating segment is as follows: (In thousands) North American OTC International OTC Consolidated Balance - March 31, 2024 Goodwill $ 711,452 $ 30,384 $ 741,836 Accumulated impairment loss (212,516) (1,587) (214,103) Balance - March 31, 2024 498,936 28,797 527,733 Adjustment related to acquisition — 309 309 Effects of foreign currency exchange rates — (823) (823) Balance - December 31, 2024 Goodwill 711,452 29,870 741,322 Accumulated impairment loss (212,516) (1,587) (214,103) Balance - December 31, 2024 $ 498,936 $ 28,283 $ 527,219

Intangible Assets, net (Tables)

Intangible Assets, net (Tables)	9 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Reconciliation of the Activity Affecting Finite-Lived Intangible Assets	A reconciliation of the activity affecting intangible assets, net is as follows: (In thousands) Indefinite- Finite-Lived Totals Gross Carrying Amounts Balance — March 31, 2024 $ 2,167,162 $ 411,258 $ 2,578,420 Additions (a) 6,850 1,400 8,250 Effects of foreign currency exchange rates (3,511) (911) (4,422) Balance — December 31, 2024 $ 2,170,501 $ 411,747 $ 2,582,248 Accumulated Amortization Balance — March 31, 2024 $ — $ 257,837 $ 257,837 Additions — 13,975 13,975 Effects of foreign currency exchange rates — (214) (214) Balance — December 31, 2024 $ — $ 271,598 $ 271,598 Intangible assets, net - December 31, 2024 $ 2,170,501 $ 140,149 $ 2,310,650 (a) Amounts relate to our acquisition of Hydralyte intellectual property on October 1, 2024, giving us rights to the Hydralyte
Schedule of Reconciliation of the Activity Affecting Indefinite-Lived Intangible Assets	A reconciliation of the activity affecting intangible assets, net is as follows: (In thousands) Indefinite- Finite-Lived Totals Gross Carrying Amounts Balance — March 31, 2024 $ 2,167,162 $ 411,258 $ 2,578,420 Additions (a) 6,850 1,400 8,250 Effects of foreign currency exchange rates (3,511) (911) (4,422) Balance — December 31, 2024 $ 2,170,501 $ 411,747 $ 2,582,248 Accumulated Amortization Balance — March 31, 2024 $ — $ 257,837 $ 257,837 Additions — 13,975 13,975 Effects of foreign currency exchange rates — (214) (214) Balance — December 31, 2024 $ — $ 271,598 $ 271,598 Intangible assets, net - December 31, 2024 $ 2,170,501 $ 140,149 $ 2,310,650 (a) Amounts relate to our acquisition of Hydralyte intellectual property on October 1, 2024, giving us rights to the Hydralyte
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Finite-lived intangible assets are expected to be amortized over their estimated useful life, which ranges from a period of 10 to 24 years, and the estimated amortization expense for each of the five succeeding years and the periods thereafter is as follows (in thousands): (In thousands) Year Ending March 31, Amount 2025 (remaining three months ended March 31, 2025) $ 4,201 2026 16,213 2027 14,621 2028 12,286 2029 12,286 Thereafter 80,542 $ 140,149

Leases (Tables)

Leases (Tables)	9 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Schedule of Components of Lease Expense	The components of lease expense for the three and nine months ended December 31, 2024 and 2023 were as follows: Three Months Ended December 31, Nine Months Ended December 31, (In thousands) 2024 2023 2024 2023 Finance lease cost: Amortization of right-of-use assets $ 240 $ 665 $ 1,569 $ 1,994 Interest on lease liabilities 82 20 94 74 Operating lease cost 1,986 1,624 5,395 4,872 Short term lease cost 38 34 101 101 Variable lease cost 15,120 14,488 47,668 47,885 Total net lease cost $ 17,466 $ 16,831 $ 54,827 $ 54,926 The weighted average remaining lease term and weighted average discount rate were as follows: December 31, 2024 Weighted average remaining lease term (years) Operating leases 4.97 Finance leases 4.88 Weighted average discount rate Operating leases 6.53 % Finance leases 6.93 %
Schedule of Maturities of Operating Leases	As of December 31, 2024, the maturities of lease liabilities were as follows: (In thousands) Year Ending March 31, Operating Leases Finance Total 2025 (remaining three months ending March 31, 2025) $ 1,909 $ 303 $ 2,212 2026 7,592 1,211 8,803 2027 7,237 1,211 8,448 2028 6,835 1,211 8,046 2029 5,554 1,205 6,759 Thereafter 6,300 701 7,001 Total undiscounted lease payments 35,427 5,842 41,269 Less amount of lease payments representing interest (5,241) (865) (6,106) Total present value of lease payments $ 30,186 $ 4,977 $ 35,163
Schedule of Maturities of Finance Leases	As of December 31, 2024, the maturities of lease liabilities were as follows: (In thousands) Year Ending March 31, Operating Leases Finance Total 2025 (remaining three months ending March 31, 2025) $ 1,909 $ 303 $ 2,212 2026 7,592 1,211 8,803 2027 7,237 1,211 8,448 2028 6,835 1,211 8,046 2029 5,554 1,205 6,759 Thereafter 6,300 701 7,001 Total undiscounted lease payments 35,427 5,842 41,269 Less amount of lease payments representing interest (5,241) (865) (6,106) Total present value of lease payments $ 30,186 $ 4,977 $ 35,163

Other Accrued Liabilities (Tabl

Other Accrued Liabilities (Tables)	9 Months Ended
	Dec. 31, 2024
Payables and Accruals [Abstract]
Schedule of Other Accrued Liabilities	Other accrued liabilities consist of the following: (In thousands) December 31, 2024 March 31, 2024 Accrued marketing costs $ 26,364 $ 24,053 Accrued compensation costs 11,300 12,221 Accrued broker commissions 1,881 1,309 Income taxes payable 436 2,569 Accrued professional fees 8,041 5,046 Accrued production costs 6,707 4,166 Other accrued liabilities 6,186 6,790 $ 60,915 $ 56,154

Long-Term Debt (Tables)

Long-Term Debt (Tables)	9 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Schedule of Long-term Debt	Long-term debt consists of the following, as of the dates indicated: (In thousands, except percentages) December 31, 2024 March 31, 2024 2021 Senior Notes bearing interest at 3.750%, with interest payable on April 1 and October 1 of each year. The 2021 Senior Notes mature on April 1, 2031. $ 600,000 $ 600,000 2019 Senior Notes bearing interest at 5.125%, with interest payable on January 15 and July 15 of each year. The 2019 Senior Notes mature on January 15, 2028. 400,000 400,000 2012 Term B-5 Loans bearing interest at the Borrower's option at SOFR plus a margin of 2.00% plus a credit spread adjustment, due on July 1, 2028. — 135,000 Long-term debt 1,000,000 1,135,000 Less: unamortized debt costs (8,031) (9,196) Long-term debt, net $ 991,969 $ 1,125,804
Schedule of Aggregate Future Principal Payments	As of December 31, 2024, aggregate future principal payments required in accordance with the terms of the indentures governing the senior unsecured notes due 2031 (the "2021 Senior Notes") and the senior unsecured notes due 2028 (the "2019 Senior Notes") are as follows: (In thousands) Year Ending March 31, Amount 2025 (remaining three months ending March 31, 2025) $ — 2026 — 2027 — 2028 400,000 2029 — Thereafter 600,000 $ 1,000,000

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
Schedule of Carry Amounts and Fair Value Measurements	The summary below details the carrying amounts and estimated fair values of these instruments at December 31, 2024 and March 31, 2024. December 31, 2024 March 31, 2024 (In thousands) Carrying Value Fair Value Carrying Value Fair Value 2019 Senior Notes 400,000 389,500 400,000 389,000 2021 Senior Notes 600,000 526,500 600,000 522,750 2012 Term B-5 Loans — — 135,000 135,506

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Dec. 31, 2024
Stockholders' Equity Note [Abstract]
Schedule of Class of Treasury Stock	Our share repurchases consisted of the following: Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Shares repurchased pursuant to the provisions of the various employee restricted stock awards: Number of shares — — 83,124 88,953 Average price per share — $ — $70.16 $61.92 Total amount repurchased — $ — $5.8 million $5.5 million Shares repurchased in conjunction with our share repurchase program: Number of shares 34,104 — 599,948 426,479 Average price per share $70.43 $ — $67.00 $58.62 Total amount repurchased $2.4 million $ — $40.2 million $25.0 million

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	9 Months Ended
	Dec. 31, 2024
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Loss	Accumulated other comprehensive loss consisted of the following at December 31, 2024 and March 31, 2024: (In thousands) December 31, 2024 March 31, 2024 Components of Accumulated Other Comprehensive Loss Cumulative translation adjustment $ (40,889) $ (35,220) Unrecognized net gain on pension plans, net of tax of $(217) and $(217), respectively 725 725 Accumulated other comprehensive loss, net of tax $ (40,164) $ (34,495)

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Dec. 31, 2024
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Earnings Per Share	The following table sets forth the computation of basic and diluted earnings per share: Three Months Ended December 31, Nine Months Ended December 31, (In thousands, except per share data) 2024 2023 2024 2023 Numerator Net income $ 61,032 $ 53,046 $ 164,477 $ 159,881 Denominator Denominator for basic earnings per share — weighted average shares outstanding 49,597 49,740 49,711 49,731 Dilutive effect of unvested restricted stock units and options issued to employees and directors 396 385 374 403 Denominator for diluted earnings per share 49,993 50,125 50,085 50,134 Earnings per Common Share: Basic earnings per share $ 1.23 $ 1.07 $ 3.31 $ 3.21 Diluted earnings per share $ 1.22 $ 1.06 $ 3.28 $ 3.19

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Compensation Expense Information	The following table provides information regarding our stock-based compensation: Three Months Ended December 31, Nine Months Ended December 31, (In thousands) 2024 2023 2024 2023 Pre-tax stock-based compensation costs charged against income $ 2,865 $ 2,449 $ 8,424 $ 10,283 Income tax benefit recognized on compensation costs $ 356 $ 241 $ 1,085 $ 910 Total fair value of options and RSUs vested during the period $ — $ — $ 12,185 $ 12,213 Cash received from the exercise of stock options $ 8,748 $ 1,635 $ 12,340 $ 10,818 Tax benefits realized from tax deductions resulting from RSU issuances and stock option exercises $ 319 $ 351 $ 1,361 $ 1,490
Schedule of Restricted Shares	A summary of the RSUs granted under the 2005 Plan and the 2020 Plan is presented below: RSUs Shares (in thousands) Weighted Nine Months Ended December 31, 2023 Unvested at March 31, 2023 409.0 $ 47.17 Granted 157.1 62.06 Incremental performance shares 41.4 — Vested (205.0) 43.17 Forfeited (10.6) 52.68 Unvested at December 31, 2023 391.9 54.43 Vested at December 31, 2023 110.2 38.77 Nine Months Ended December 31, 2024 Unvested at March 31, 2024 391.9 $ 54.43 Granted 145.7 69.70 Incremental performance shares 41.1 — Vested (192.7) 47.60 Forfeited (4.9) 59.31 Unvested at December 31, 2024 381.1 62.57 Vested at December 31, 2024 108.5 40.87
Schedule of Fair Value of Options Granted	The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions presented below: Nine Months Ended December 31, 2024 2023 Expected volatility 30.4% - 30.8% 30.2% - 31.6% Expected dividends $ — $ — Expected term in years 6.0 to 7.0 6.0 to 7.0 Risk-free rate 4.5% 3.6% to 4.1% Weighted average grant date fair value of options granted $ 27.97 $ 23.79
Schedule of Stock Option Activity	A summary of option activity under the 2005 Plan and the 2020 Plan is as follows: Options Shares (in thousands) Weighted Weighted Aggregate Nine Months Ended December 31, 2023 Outstanding at March 31, 2023 1,081.0 $ 43.96 Granted 131.1 61.81 Exercised (268.9) 40.23 Forfeited (41.0) 54.15 Expired (2.8) 54.47 Outstanding at December 31, 2023 899.4 47.18 6.2 $ 12,703 Vested at December 31, 2023 606.2 43.23 5.0 $ 10,903 Nine Months Ended December 31, 2024 Outstanding at March 31, 2024 728.0 $ 48.30 Granted 109.7 69.94 Exercised (243.9) 50.59 Forfeited (15.6) 60.87 Outstanding at December 31, 2024 578.2 51.10 6.8 $ 15,608 Vested at December 31, 2024 349.9 42.65 5.7 $ 12,399

Business Segments (Tables)

Business Segments (Tables)	9 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Schedule of Operating and Reportable Segments	The tables below summarize information about our reportable segments. Three Months Ended December 31, 2024 (In thousands) North American OTC International OTC Consolidated Total segment revenues* $ 238,934 $ 51,383 $ 290,317 Cost of sales 108,067 21,201 129,268 Gross profit 130,867 30,182 161,049 Advertising and marketing 30,995 6,950 37,945 Contribution margin $ 99,872 $ 23,232 $ 123,104 Other operating expenses 31,142 Operating income $ 91,962 * Intersegment revenues of $0.9 million were eliminated from the North American OTC Healthcare segment. Nine Months Ended December 31, 2024 (In thousands) North American OTC International OTC Consolidated Total segment revenues* 711,061 $ 130,183 $ 841,244 Cost of sales 321,408 55,383 376,791 Gross profit 389,653 74,800 464,453 Advertising and marketing 99,637 19,082 118,719 Contribution margin $ 290,016 $ 55,718 $ 345,734 Other operating expenses 97,387 Operating income $ 248,347 * Intersegment revenues of $2.5 million were eliminated from the North American OTC Healthcare segment. Three Months Ended December 31, 2023 (In thousands) North American OTC International OTC Consolidated Total segment revenues* $ 236,565 $ 46,176 $ 282,741 Cost of sales 106,090 18,713 124,803 Gross profit 130,475 27,463 157,938 Advertising and marketing 33,917 5,549 39,466 Contribution margin $ 96,558 $ 21,914 $ 118,472 Other operating expenses 31,640 Operating income $ 86,832 * Intersegment revenues of $0.5 million were eliminated from the North American OTC Healthcare segment. Nine Months Ended December 31, 2023 (In thousands) North American OTC International OTC Consolidated Total segment revenues* $ 727,131 $ 121,235 $ 848,366 Cost of sales 323,632 52,103 375,735 Gross profit 403,499 69,132 472,631 Advertising and marketing 100,707 15,092 115,799 Contribution margin $ 302,792 $ 54,040 $ 356,832 Other operating expenses 96,556 Operating income $ 260,276 * Intersegment revenues of $2.5 million were eliminated from the North American OTC Healthcare segment.
Schedule of Revenues from Similar Product Groups	The tables below summarize information about our segment revenues from similar product groups. Three Months Ended December 31, 2024 (In thousands) North American OTC International OTC Consolidated Analgesics $ 29,314 $ 1,668 $ 30,982 Cough & Cold 22,984 6,347 29,331 Women's Health 53,686 4,439 58,125 Gastrointestinal 42,521 26,469 68,990 Eye & Ear Care 38,895 6,783 45,678 Dermatologicals 28,546 2,109 30,655 Oral Care 19,869 3,211 23,080 Other OTC 3,119 357 3,476 Total segment revenues $ 238,934 $ 51,383 $ 290,317 Nine Months Ended December 31, 2024 (In thousands) North American OTC International OTC Consolidated Analgesics $ 83,472 $ 4,025 $ 87,497 Cough & Cold 60,999 18,304 79,303 Women's Health 158,490 14,560 173,050 Gastrointestinal 128,719 58,347 187,066 Eye & Ear Care 118,354 18,240 136,594 Dermatologicals 93,789 6,076 99,865 Oral Care 58,241 9,696 67,937 Other OTC 8,997 935 9,932 Total segment revenues $ 711,061 $ 130,183 $ 841,244 Three Months Ended December 31, 2023 (In thousands) North American OTC International OTC Consolidated Analgesics $ 28,680 $ 1,586 $ 30,266 Cough & Cold 27,359 5,814 33,173 Women's Health 53,076 5,190 58,266 Gastrointestinal 38,919 22,707 61,626 Eye & Ear Care 38,503 6,569 45,072 Dermatologicals 26,603 1,165 27,768 Oral Care 20,362 3,100 23,462 Other OTC 3,063 45 3,108 Total segment revenues $ 236,565 $ 46,176 $ 282,741 Nine Months Ended December 31, 2023 (In thousands) North American OTC International OTC Consolidated Analgesics $ 85,838 $ 3,814 $ 89,652 Cough & Cold 73,703 19,129 92,832 Women's Health 163,031 17,218 180,249 Gastrointestinal 122,303 49,678 171,981 Eye & Ear Care 117,719 17,715 135,434 Dermatologicals 94,299 3,972 98,271 Oral Care 61,400 9,591 70,991 Other OTC 8,838 118 8,956 Total segment revenues $ 727,131 $ 121,235 $ 848,366

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Mar. 31, 2024
Inventory Disclosure [Abstract]
Packaging and raw materials	$ 19,437	$ 19,210
Work in process	3,042	636
Finished goods	129,037	118,871
Inventories	$ 151,516	$ 138,717

Inventories - Narrative (Detail

Inventories - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2024	Mar. 31, 2024
Inventory Disclosure [Abstract]
Inventory valuation reserves related to obsolete and slow-moving inventory	$ 5.2	$ 4.7

Goodwill - Schedule of Changes

Goodwill - Schedule of Changes (Details) $ in Thousands	9 Months Ended
	Dec. 31, 2024 USD ($)
Goodwill [Roll Forward]
Goodwill, gross, beginning	$ 741,836
Accumulated impairment loss, beginning	(214,103)
Goodwill, net, beginning	527,733
Adjustment related to acquisition	309
Effects of foreign currency exchange rates	(823)
Goodwill, gross, ending	741,322
Accumulated impairment loss, ending	(214,103)
Goodwill, net, ending	527,219
North American OTC Healthcare
Goodwill [Roll Forward]
Goodwill, gross, beginning	711,452
Accumulated impairment loss, beginning	(212,516)
Goodwill, net, beginning	498,936
Adjustment related to acquisition	0
Effects of foreign currency exchange rates	0
Goodwill, gross, ending	711,452
Accumulated impairment loss, ending	(212,516)
Goodwill, net, ending	498,936
International OTC Healthcare
Goodwill [Roll Forward]
Goodwill, gross, beginning	30,384
Accumulated impairment loss, beginning	(1,587)
Goodwill, net, beginning	28,797
Adjustment related to acquisition	309
Effects of foreign currency exchange rates	(823)
Goodwill, gross, ending	29,870
Accumulated impairment loss, ending	(1,587)
Goodwill, net, ending	$ 28,283

Intangible Assets, net - Schedu

Intangible Assets, net - Schedule of Activity Affecting Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Mar. 31, 2024
Intangible Assets, Gross [Abstract]
Totals, gross, beginning balance			$ 2,578,420
Intangible assets, additions			8,250
Totals, effects of foreign currency exchange rate			(4,422)
Totals, gross, ending balance	$ 2,582,248		2,582,248
Accumulated Amortization
Accumulated amortization, beginning balance			257,837
Accumulated amortization, additions	4,200	$ 4,900	13,975	$ 14,800
Accumulated amortization, effects of foreign exchange rates			(214)
Accumulated amortization, ending balance	271,598		271,598
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, net	140,149		140,149
Intangible Assets, Net [Abstract]
Intangible assets, net	2,310,650		2,310,650		$ 2,320,583
Finite-Lived Trademarks and Customer Relationships
Finite-Lived Trademarks and Customer Relationships
Finite-lived trademarks and customer relationships, beginning balance			411,258
Finite-Lived trademarks and customer relationships, additions			1,400
Finite-lived trademarks and customer relationships, effects of foreign currency exchange rate			(911)
Finite-lived trademarks and customer relationships, ending balance	411,747		411,747
Accumulated Amortization
Accumulated amortization, beginning balance			257,837
Accumulated amortization, additions			13,975
Accumulated amortization, effects of foreign exchange rates			(214)
Accumulated amortization, ending balance	271,598		271,598
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, net	140,149		140,149
Indefinite- Lived Trademarks
Indefinite- Lived Trademarks
Indefinite-lived trademarks, beginning balance			2,167,162
Indefinite-lived trade marks, additions			6,850
Indefinite lived trademarks, effects of foreign currency exchange rate			(3,511)
Indefinite-lived trademarks, ending balance	$ 2,170,501		$ 2,170,501

Intangible Assets, net - Narrat

Intangible Assets, net - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 4,200	$ 4,900	$ 13,975	$ 14,800
Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	10 years		10 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	24 years		24 years

Intangible Assets, net - Sche_2

Intangible Assets, net - Schedule of Future Amortization of Intangible Assets (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2025 (remaining three months ended March 31, 2025)	$ 4,201
2026	16,213
2027	14,621
2028	12,286
2029	12,286
Thereafter	80,542
Finite-lived intangible assets, net	$ 140,149

Leases - Schedule of Lease Cost

Leases - Schedule of Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Leases [Abstract]
Amortization of right-of-use assets	$ 240	$ 665	$ 1,569	$ 1,994
Interest on lease liabilities	82	20	94	74
Operating lease cost	1,986	1,624	5,395	4,872
Short term lease cost	38	34	101	101
Variable lease cost	15,120	14,488	47,668	47,885
Total net lease cost	$ 17,466	$ 16,831	$ 54,827	$ 54,926

Leases - Schedule of Lease Matu

Leases - Schedule of Lease Maturities (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Operating Leases
2025 (remaining three months ending March 31, 2025)	$ 1,909
2026	7,592
2027	7,237
2028	6,835
2029	5,554
Thereafter	6,300
Total undiscounted lease payments	35,427
Less amount of lease payments representing interest	(5,241)
Total present value of lease payments	30,186
Finance Lease
2025 (remaining three months ending March 31, 2025)	303
2026	1,211
2027	1,211
2028	1,211
2029	1,205
Thereafter	701
Total undiscounted lease payments	5,842
Less amount of lease payments representing interest	(865)
Total present value of lease payments	4,977
Total
2025 (remaining three months ending March 31, 2025)	2,212
2026	8,803
2027	8,448
2028	8,046
2029	6,759
Thereafter	7,001
Total undiscounted lease payments	41,269
Less amount of lease payments representing interest	(6,106)
Total present value of lease payments	$ 35,163

Leases - Schedule of Weighted A

Leases - Schedule of Weighted Average Remaining Lease Term and Weighted Average Discount Rate (Details)	Dec. 31, 2024
Weighted average remaining lease term (years)
Operating leases	4 years 11 months 19 days
Finance leases	4 years 10 months 17 days
Weighted average discount rate
Operating leases	6.53%
Finance leases	6.93%

Leases - Narrative (Details)

Leases - Narrative (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Oct. 01, 2024	Mar. 31, 2024
Lessee, Lease, Description [Line Items]
Operating lease right-of-use assets	$ 29,658		$ 11,285
Operating lease liability	30,186
Finance lease liability	$ 4,977
GEODIS
Lessee, Lease, Description [Line Items]
Renewal term		65 months
Operating lease right-of-use assets		$ 23,000
Operating lease liability		23,000
Finance lease, right-of-use asset		4,700
Finance lease liability		$ 4,700

Other Accrued Liabilities (Deta

Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Mar. 31, 2024
Payables and Accruals [Abstract]
Accrued marketing costs	$ 26,364	$ 24,053
Accrued compensation costs	11,300	12,221
Accrued broker commissions	1,881	1,309
Income taxes payable	436	2,569
Accrued professional fees	8,041	5,046
Accrued production costs	6,707	4,166
Other accrued liabilities	6,186	6,790
Total other accrued liabilities	$ 60,915	$ 56,154

Long-Term Debt - Schedule of Lo

Long-Term Debt - Schedule of Long-term Debt (Details) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2024	Mar. 31, 2024
Debt Instrument [Line Items]
Total long-term debt (including current portion)	$ 1,000,000
Long-term debt, net	1,000,000	$ 1,135,000
Less: unamortized debt costs	(8,031)	(9,196)
Long-term debt, net	$ 991,969	1,125,804
Senior Notes | 2021 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate	3.75%
Total long-term debt (including current portion)	$ 600,000	600,000
Senior Notes | 2019 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate	5.125%
Total long-term debt (including current portion)	$ 400,000	400,000
Term Loans | 2012 Term B-5 Loans
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	2%
Term Loans | 2012 Term B-5 Loans
Debt Instrument [Line Items]
Total long-term debt (including current portion)	$ 0	$ 135,000

Long-Term Debt - Narrative (Det

Long-Term Debt - Narrative (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Debt Instrument [Line Items]
Long-term debt outstanding	$ 1,000,000
Revolving Credit Facility | 2012 ABL Revolver
Debt Instrument [Line Items]
Long-term debt outstanding	0
Borrowing capacity	$ 163,800

Long-Term Debt - Schedule of Ma

Long-Term Debt - Schedule of Maturities of Long-term Debt (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Aggregate Future Principal Payments
2025 (remaining three months ending March 31, 2025)	$ 0
2026	0
2027	0
2028	400,000
2029	0
Thereafter	600,000
Total long-term debt (including current portion)	$ 1,000,000

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Mar. 31, 2024
Senior Notes | 2019 Senior Notes | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	$ 400,000	$ 400,000
Senior Notes | 2021 Senior Notes | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	600,000	600,000
Term Loans | 2012 Term B-5 Loans | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	0	135,000
Fair Value | Senior Notes | 2019 Senior Notes | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	389,500	389,000
Fair Value | Senior Notes | 2021 Senior Notes | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	526,500	522,750
Fair Value | Term Loans | 2012 Term B-5 Loans | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	$ 0	$ 135,506

Stockholders' Equity - Narrativ

Stockholders' Equity - Narrative (Details)	9 Months Ended
	Dec. 31, 2024 USD ($) vote $ / shares shares	May 06, 2024 USD ($)	Mar. 31, 2024 $ / shares shares
Stockholders' Equity Note [Abstract]
Common stock, shares authorized (in shares) | shares	250,000,000		250,000,000
Common stock, par value (in USD per share) | $ / shares	$ 0.01		$ 0.01
Preferred stock, shares authorized (in shares) | shares	5,000,000		5,000,000
Preferred stock, par value (in USD per share) | $ / shares	$ 0.01		$ 0.01
Voting rights, number of votes per common share owned | vote	1
Dividends declared on common stock | $	$ 0
Stock repurchase program, authorized amount | $		$ 300,000,000

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Repurchased Shares (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Class of Stock [Line Items]
Total amount repurchased	$ 2,345		$ 46,222	$ 30,524
Share Repurchase Program
Class of Stock [Line Items]
Number of shares (in shares)	34,104	0	599,948	426,479
Average price per share (in USD per share)	$ 70.43	$ 0	$ 67	$ 58.62
Total amount repurchased	$ 2,400	$ 0	$ 40,200	$ 25,000
Restricted Shares
Class of Stock [Line Items]
Number of shares (in shares)	0	0	83,124	88,953
Average price per share (in USD per share)	$ 0	$ 0	$ 70.16	$ 61.92
Total amount repurchased	$ 0	$ 0	$ 5,800	$ 5,500

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss - Schedule of Components of AOCL (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Sep. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Mar. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shareholders' equity	$ 1,788,433	$ 1,731,761	$ 1,655,084	$ 1,600,577	$ 1,535,959	$ 1,447,084
Accumulated other comprehensive loss, net of tax
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shareholders' equity	(40,164)	$ (26,536)	(34,495)	$ (28,529)	$ (35,994)	$ (31,564)
Cumulative translation adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shareholders' equity	(40,889)		(35,220)
Unrecognized net gain on pension plans, net of tax of $(217) and $(217), respectively
Accumulated Other Comprehensive Income (Loss) [Line Items]
Unrecognized net gain on pension plan, tax	(217)		(217)
Shareholders' equity	$ 725		$ 725

Accumulated Other Comprehensi_4

Accumulated Other Comprehensive Loss - Narrative (Details) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2024	Mar. 31, 2024
Stockholders' Equity Note [Abstract]
Reclassification from accumulated other comprehensive loss into earnings	$ 0	$ 0

Earnings Per Share - Schedule o

Earnings Per Share - Schedule of Computation of Basis and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Numerator
Net income	$ 61,032	$ 53,046	$ 164,477	$ 159,881
Denominator
Denominator for basic earnings per share — weighted average shares outstanding (in shares)	49,597	49,740	49,711	49,731
Dilutive effect of unvested restricted stock units and options issued to employees and directors (in shares)	396	385	374	403
Denominator for diluted earnings per share (in shares)	49,993	50,125	50,085	50,134
Earnings per Common Share:
Basic earnings per share (in USD per share)	$ 1.23	$ 1.07	$ 3.31	$ 3.21
Diluted earnings per share (in USD per share)	$ 1.22	$ 1.06	$ 3.28	$ 3.19

Earnings Per Share - Antidiluti

Earnings Per Share - Antidilutive Securities Narrative (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Outstanding Stock Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	0.1	0.3	0.2	0.3

Stock-Based Compensation - Narr

Stock-Based Compensation - Narrative (Details) - USD ($) $ in Millions		1 Months Ended	9 Months Ended
	Jan. 06, 2025	Jun. 30, 2014	Dec. 31, 2024	Jun. 23, 2020	May 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs related to nonvested awards			$ 3.2
Unrecognized compensation costs related to nonvested awards, weighted average period for recognition (years)			1 year 10 months 24 days
Options exercised, aggregate intrinsic value			$ 6.6
Restricted Stock Units (RSUs) & Performance Stock Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs related to nonvested awards			$ 12.2
Unrecognized compensation costs related to nonvested awards, weighted average period for recognition (years)			1 year 10 months 24 days
Restricted Shares | Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	21,136
Award vesting period	4 years
Long-term Equity Incentive Plan, 2005
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for grant (in shares)					5,000,000
Number of additional shares authorized (in shares)		1,800,000
Long-term Incentive Plan, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)			1,600,000	2,827,210
Number of new shares for future issuance under 2020 long-term incentive plans (in shares)				2,000,000
Number of unissued shares reserved for 2020 long-term incentive plans (in shares)				827,210

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Stock Based Compensation Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Pre-tax stock-based compensation costs charged against income	$ 2,865	$ 2,449	$ 8,424	$ 10,283
Income tax benefit recognized on compensation costs	356	241	1,085	910
Total fair value of options and RSUs vested during the period	0	0	12,185	12,213
Cash received from the exercise of stock options	8,748	1,635	12,340	10,818
Tax benefits realized from tax deductions resulting from RSU issuances and stock option exercises	$ 319	$ 351	$ 1,361	$ 1,490

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) - $ / shares	9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Shares
Outstanding, beginning of period (in shares)	391,900	409,000
Granted (in shares)	145,700	157,100
Incremental performance shares (in shares)	41,100	41,400
Vested (in shares)	(192,700)	(205,000)
Forfeited (in shares)	(4,900)	(10,600)
Outstanding, end of period (in shares)	381,100	391,900
Vested, end of period (in shares)	108,500	110,200
Weighted Average Grant-Date Fair Value
Outstanding, beginning of period, weighted-average grant-date fair value (in USD per share)	$ 54.43	$ 47.17
Granted, weighted-average grant-date fair value (in USD per share)	69.70	62.06
Vested, weighted-average grant-date fair value (in USD per share)	47.60	43.17
Forfeited, weighted-average grant-date fair value (in USD per share)	59.31	52.68
Outstanding, end of period, weighted-average grant-date fair value (in USD per share)	62.57	54.43
Vested, end of period, weighted-average grant-date fair value (in USD per share)	$ 40.87	$ 38.77

Stock-Based Compensation - Sc_3

Stock-Based Compensation - Schedule of Stock Option Valuation Assumptions (Details) - Stock Options - USD ($)	9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividends	$ 0	$ 0
Risk-free rate	4.50%
Granted, weighted-average grant-date fair value (in USD per share)	$ 27.97	$ 23.79
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	30.40%	30.20%
Expected term in years	6 years	6 years
Risk-free rate		3.60%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	30.80%	31.60%
Expected term in years	7 years	7 years
Risk-free rate		4.10%

Stock-Based Compensation - Sc_4

Stock-Based Compensation - Schedule of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Shares
Outstanding, beginning of period (in shares)	728,000	1,081,000
Granted (in shares)	109,700	131,100
Exercised (in shares)	(243,900)	(268,900)
Forfeited (in shares)	(15,600)	(41,000)
Expired (in shares)		(2,800)
Outstanding, end of period (in shares)	578,200	899,400
Exercisable, end of period (in shares)	349,900	606,200
Weighted Average Exercise Price
Outstanding, beginning of period, weighted-average exercise price (in USD per share)	$ 48.30	$ 43.96
Granted, weighted-average exercise price (in USD per share)	69.94	61.81
Exercised, weighted-average exercise price (in USD per share)	50.59	40.23
Forfeited, weighted-average exercise price (in USD per share)	60.87	54.15
Expired, weighted-average exercise price (in USD per share)		54.47
Outstanding, end of period, weighted-average exercise price (in USD per share)	51.10	47.18
Exercisable, end of period, weighted-average exercise price (in USD per share)	$ 42.65	$ 43.23
Options, Additional Disclosures:
Outstanding, end of period, weighted-average remaining contractual term	6 years 9 months 18 days	6 years 2 months 12 days
Exercisable, end of period, weighted-average remaining contractual term	5 years 8 months 12 days	5 years
Outstanding, end of period, aggregate intrinsic value	$ 15,608	$ 12,703
Exercisable, end of period, aggregate intrinsic value	$ 12,399	$ 10,903

Income Taxes (Details)

Income Taxes (Details)	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Effective income tax rate	23.90%	23.80%	21.80%	23.40%

Concentrations of Risk (Details

Concentrations of Risk (Details) - manufacturer	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Concentration Risk [Line Items]
Number of third-party manufacturers	102	129	102	129
Sales | Customer Concentration Risk | Walmart
Concentration Risk [Line Items]
Concentration risk, percentage	20%	19%	20%	20%
Sales | Customer Concentration Risk | Amazon
Concentration Risk [Line Items]
Concentration risk, percentage	12%	11%	12%	10%
Sales | Supplier Concentration Risk
Concentration Risk [Line Items]
Number of third-party manufacturers with long-term contracts			27	27
Top 5 brands | Sales | Product Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	38%	37%	37%	38%
Manufacturers | Sales | Supplier Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage			73%	72%
Contract Pharmacal Corporation | Sales | Supplier Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage			21%	20%

Business Segments - Schedule of

Business Segments - Schedule of Information on Operating and Reportable Segments (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Segment Reporting Information, Profit (Loss):
Total revenues	$ 290,317	$ 282,741	$ 841,244	$ 848,366
Cost of sales	129,268	124,803	376,791	375,735
Gross profit	161,049	157,938	464,453	472,631
Advertising and marketing	37,945	39,466	118,719	115,799
Contribution margin	123,104	118,472	345,734	356,832
Other operating expenses	31,142	31,640	97,387	96,556
Operating income	91,962	86,832	248,347	260,276
North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	238,934	236,565	711,061	727,131
International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	51,383	46,176	130,183	121,235
Operating Segments | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	238,934	236,565	711,061	727,131
Cost of sales	108,067	106,090	321,408	323,632
Gross profit	130,867	130,475	389,653	403,499
Advertising and marketing	30,995	33,917	99,637	100,707
Contribution margin	99,872	96,558	290,016	302,792
Operating Segments | International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	51,383	46,176	130,183	121,235
Cost of sales	21,201	18,713	55,383	52,103
Gross profit	30,182	27,463	74,800	69,132
Advertising and marketing	6,950	5,549	19,082	15,092
Contribution margin	23,232	21,914	55,718	54,040
Intersegment Eliminations | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	$ 900	$ 500	$ 2,500	$ 2,500

Business Segments - Schedule _2

Business Segments - Schedule of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	$ 290,317	$ 282,741	$ 841,244	$ 848,366
Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	30,982	30,266	87,497	89,652
Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	29,331	33,173	79,303	92,832
Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	58,125	58,266	173,050	180,249
Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	68,990	61,626	187,066	171,981
Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	45,678	45,072	136,594	135,434
Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	30,655	27,768	99,865	98,271
Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	23,080	23,462	67,937	70,991
Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	3,476	3,108	9,932	8,956
North American OTC Healthcare
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	238,934	236,565	711,061	727,131
North American OTC Healthcare | Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	29,314	28,680	83,472	85,838
North American OTC Healthcare | Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	22,984	27,359	60,999	73,703
North American OTC Healthcare | Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	53,686	53,076	158,490	163,031
North American OTC Healthcare | Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	42,521	38,919	128,719	122,303
North American OTC Healthcare | Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	38,895	38,503	118,354	117,719
North American OTC Healthcare | Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	28,546	26,603	93,789	94,299
North American OTC Healthcare | Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	19,869	20,362	58,241	61,400
North American OTC Healthcare | Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	3,119	3,063	8,997	8,838
International OTC Healthcare
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	51,383	46,176	130,183	121,235
International OTC Healthcare | Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	1,668	1,586	4,025	3,814
International OTC Healthcare | Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	6,347	5,814	18,304	19,129
International OTC Healthcare | Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	4,439	5,190	14,560	17,218
International OTC Healthcare | Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	26,469	22,707	58,347	49,678
International OTC Healthcare | Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	6,783	6,569	18,240	17,715
International OTC Healthcare | Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	2,109	1,165	6,076	3,972
International OTC Healthcare | Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	3,211	3,100	9,696	9,591
International OTC Healthcare | Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	$ 357	$ 45	$ 935	$ 118